Grifols drops as Q1 profit rises, dividend plan and guidance reiterated
Grifols reported Q1 2026 results today, posting net profit of €73 million (+21.9% YoY) on €1.7 billion of revenue and confirming its 2026 outlook. It also said it expects shareholders to approve a final cash dividend charged to 2025 and reiterated it is evaluating a potential IPO of its U.S. Biopharma business.
1. Today’s catalyst (May 7, 2026)
Grifols released Q1 2026 financial results today, reporting net profit of €73 million, up 21.9% year over year, with revenue of about €1.7 billion and EBITDA of €381 million (margin ~22.4%). The company said the quarter’s performance supported its full-year 2026 guidance and also discussed capital-return and strategic actions alongside the quarterly update. (europapress.es)
2. Dividend and strategic update alongside results
Along with the quarterly figures, Grifols indicated it expects its shareholder meeting to approve a final cash dividend charged to 2025 and reiterated it is evaluating a potential IPO of its U.S. Biopharma business. These items can move the stock intraday by shifting sentiment around capital returns, leverage, and long-term structure. (cincodias.elpais.com)
3. Why the stock could be down despite “good” headlines
Even with higher net profit, the market can react negatively if reported results were below expectations, if FX headwinds pressured reported growth, or if investors focused on leverage/cash-flow details rather than net income. Today’s move appears tied to digestion of the Q1 print and accompanying guidance/dividend/IPO commentary rather than a separate corporate action. (cincodias.elpais.com)